|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Calithera Biosciences, Inc. (CALA) |
|
|
$0.02 0.00 (0.00%) as of 4:30 Wed 4/24
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
97,237,000 |
| Market
Cap: |
1.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.015 - $0.365 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Calithera Biosciences is a clinical-stage precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Co.'s product candidate, CB-280, is an oral inhibitor of arginase, developed for the treatment of cystic fibrosis. Co. has also identified CB-668, an orally administered inhibitor of the immune-suppressive enzyme IL4I1. An additional arginase inhibitor, INCB001158, was discovered by Co. and is being developed by Incyte Corporation for oncology and hematology indications. Co. has developed CB-708, a selective, orally-bioavailable small molecule inhibitor of CD73.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
121,333 |
| Total Sell Value |
$0 |
$0 |
$0 |
$46,810 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ray Sumita |
See Remarks |
• – – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
105,000 |
|
- |
|
| Kuriakose Emil |
CHIEF MEDICAL OFFICER |
• – – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
72,467 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
171,314 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
210,871 |
|
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
102,500 |
|
- |
|
| Orford Keith |
Director |
– • – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
196,094 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2021-11-05 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
179,435 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2021-10-28 |
4 |
D |
$1.89 |
$86,874 |
D/D |
(45,965) |
149,435 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2021-10-28 |
4 |
D |
$1.89 |
$86,874 |
D/D |
(45,965) |
180,871 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2021-10-28 |
4 |
D |
$1.89 |
$86,874 |
D/D |
(45,965) |
141,314 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2021-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
195,400 |
|
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2021-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
36,000 |
90,500 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2021-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
226,836 |
|
- |
|
| Ray Sumita |
See Remarks |
• – – |
2021-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
36,000 |
93,000 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2021-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
187,279 |
|
- |
|
| Orford Keith |
CHIEF MEDICAL OFFICER |
• – – |
2021-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
166,094 |
|
- |
|
| Ray Sumita |
See Remarks |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
57,000 |
|
- |
|
| Molineaux Christopher |
SR. VP, DEVELOPMENT |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
52,000 |
|
- |
|
| Hecht Curtis |
CHIEF BUSINESS OFFICER |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
92,321 |
|
- |
|
| Orford Keith |
CHIEF MEDICAL OFFICER |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
76,094 |
|
- |
|
| Molineaux Susan |
PRESIDENT & CEO |
• • – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
95,000 |
|
- |
|
| Sjogren Eric |
SR. VP, DRUG DISCOVERY |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
134,336 |
|
- |
|
| Wong Stephanie |
See Remarks |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
103,156 |
|
- |
|
| Parlati Francesco |
SR. VP, RESEARCH |
• – – |
2021-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
105,400 |
|
- |
|
| Orford Keith |
Chief Medical Officer |
• – – |
2020-12-16 |
4 |
AS |
$6.00 |
$14,682 |
D/D |
(2,447) |
11,094 |
|
-60% |
|
141 Records found
|
|
Page 2 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
